Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
Go back to Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026| Avalon Technology Group, Inc. (NASDAQ: AVLN) | Delayed: 30.17 -2.75 (8.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.92 | 52 Week High | $0.00 | |||
| Open | $32.92 | 52 Week Low | $0.00 | |||
| Day High | $32.92 | P/E | N/A | |||
| Day Low | $29.57 | EPS | $0.00 | |||
| Volume | 785,937 | |||||
